A Phase I, Open-label, Single-center Study to Assess the Pharmacokinetics of a Single Oral Dose of VIMOVO (250 mg Naproxen/20 mg Esomeprazole)in Healthy Adult Subjects
This is an assessment of Pharmacokinetics of a single oral dose of VIMOVO in healthy adult volunteers.